Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1996, for Gilead Sciences, Inc., a biopharmaceutical company focused on research and development. The company has been unprofitable since its inception in 1987. A significant milestone occurred on June 26, 1996, when the FDA granted marketing clearance for VISTIDE (cidofovir injection) for the treatment of cytomegalovirus retinitis in AIDS patients. Gilead began independently marketing VISTIDE in the United States during this period.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1996 | Six Months Ended June 30, 1996 |
|---|---|---|
| Total Revenues | $2.2 million | $3.0 million |
| Net Loss | $(12.2) million | $(23.0) million |
| Net Loss Per Share | $(0.43) | $(0.85) |
| Research & Development Expenses | $10.6 million | $19.8 million |
| Selling, General & Admin Expenses | $7.4 million | $12.3 million |
| Cash and Cash Equivalents (End of Period) | $182.9 million | $182.9 million |
| Short-term Investments | $107.5 million | $107.5 million |
| Total Current Liabilities | $14.6 million | $14.6 million |
| Accumulated Deficit | $(135.7) million | $(135.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased significantly compared to the prior year periods, driven by the launch of VISTIDE which generated $1.4 million in net product sales for the quarter and six months ended June 30, 1996. Contract sales decreased slightly year-over-year.
- Expense Increases:
- Research and development (R&D) expenses rose 41% for the quarter and 27% for the six-month period, attributed to ongoing clinical trials and increased staffing.
- Selling, general, and administrative (SG&A) expenses surged 208% for the quarter and 136% for the six-month period, primarily due to establishing marketing and sales capabilities for VISTIDE.
- Liquidity Expansion: Cash and cash equivalents increased from $27.4 million at December 31, 1995, to $182.9 million at June 30, 1996. This was primarily due to a public offering of common stock in February 1996, which generated approximately $155.6 million in net proceeds.
- Interest Income: Net interest income increased 270% for the quarter and significantly for the six-month period, resulting from higher average cash and investment balances.
Guidance, Outlook, and Risks
Outlook: Management expects to incur substantial losses for the next several years due to R&D programs and marketing efforts. R&D and SG&A expenses are expected to grow significantly in the remainder of 1996. The company anticipates construction and equipment costs of approximately $3.0 million for a new facility to be occupied by October 1996.
Capital Needs: While current capital resources are deemed adequate for the foreseeable future, the company expects cash requirements to grow. Additional equity or debt financing may be required, though there is no assurance such funds will be available on favorable terms.
Risks and Contingencies:
- Development Risks: Product candidates may fail in clinical trials, be found toxic, or fail to receive regulatory approval.
- Market Risks: Uncertainty regarding market acceptance of VISTIDE and future products, as well as pricing pressures from payors.
- Competition: Intense competition from pharmaceutical and biotechnology companies.
- Profitability: No assurance that the company will ever achieve or sustain profitability.
Investor Verification Checklist
- Verify the commercial performance and sales trajectory of VISTIDE following its June 1996 launch.
- Monitor the burn rate of cash given the significant increase in R&D and SG&A expenses.
- Assess the progress and outcomes of ongoing clinical trials for other product candidates.
- Review the status of collaborative agreements, specifically the extended agreement with Glaxo.
- Track the company's ability to secure additional financing if required to fund future operations.